Lilly Asia Ventures
VC Fund
Shanghai, China
Lilly Asia Ventures is a VC fund in Shanghai focused on Biotechnology and Health Care. Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.
- Total investments:
- 254
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $40M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lilly Asia Ventures invests in
Stages Lilly Asia Ventures invests in
Countries Lilly Asia Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $14M–$100M
- Series B
- $25M–$110M
- Series C
- $30M–$308M
Investment Focus
Industry
- Biotechnology 98 (39%)
- Health Care 73 (29%)
- Medical 54 (21%)
- Pharmaceutical 38 (15%)
- Therapeutics 28 (11%)
Stage
- Series A 66 (26%)
- Series B 65 (26%)
- Series C 35 (14%)
- Series D 11 (4%)
- Venture - Series Unknown 11 (4%)
Country
- China 83 (33%)
- United States 46 (18%)
- Hong Kong 4 (2%)
- Canada 1 (0%)
- Israel 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jiaxin Li
partner
|
partner | Total investments: 1 | Find email | |
Judith Li
Partner
|
Partner | Total investments: 11 | Find email | |
Stella Shi
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Yi Shi
Managing Director & Founder
|
Managing Director & Founder | Total investments: 15 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Connexus Therapeutics
|
Connexus Therapeutics is a private, venture-backed biotechnology company specializing in the discovery and development of next-generation small-molecule drugs for oncology treatment . | $5M / Series A / Sep 17, 2026 | |
| NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. | $80M / Series B / Sep 03, 2026 | ||
Convergen
|
Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates | $15M / Seed / Aug 31, 2026 | |
| Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases. | $50M / Series B / Aug 13, 2026 | ||
| NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs. | $435M / Series C / Jun 02, 2026 | ||
| Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. | $50M / Series C / May 18, 2026 | ||
| Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $40M / Series B / May 12, 2026 | ||
| ZSPepLib is a peptide lead drug developer, established in January 2017, coordinates Zhuzhou, Hunan. It is a platform-based company specializing in peptide lead drug discovery, focusing on the development, production, sales and new peptide drugs of the large-capacity peptide library. Screening R&D technical services. | $44.2M / Series C / May 11, 2026 | ||
| Pulnovo Medical integrates development, production and services. Our core products including use pf radiofrequency ablation technology to treat pulmonary hypertension. The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents. | $100M / Series D / Apr 20, 2026 | ||
Syneron
|
Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals. | $150M / Series B / Mar 31, 2026 | |
| See all 254 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lilly Asia Ventures invest in?
Lilly Asia Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 254 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Lilly Asia Ventures invest in?
Lilly Asia Ventures typically joins rounds of $14M–$100M at Series A, $25M–$110M at Series B and $30M–$308M at Series C. These are whole funding-round sizes, not Lilly Asia Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Lilly Asia Ventures took part in.
How do I contact Lilly Asia Ventures?
Public channels for Lilly Asia Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lilly Asia Ventures?
The team at Lilly Asia Ventures includes Jiaxin Li (partner), Judith Li (Partner) and Stella Shi (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
